HER2/NEU+ UTERINE SEROUS CARCINOMA

Clinical trials for HER2/NEU+ UTERINE SEROUS CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new HER2/NEU+ UTERINE SEROUS CARCINOMA trials appear

Sign up with your email to follow new studies for HER2/NEU+ UTERINE SEROUS CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug trial targets Tough-to-Treat uterine cancer

Disease control Recruiting now

This study is testing whether the drug afatinib can help control a specific type of aggressive uterine cancer that has returned or persisted after previous treatments. It will enroll about 50 women whose cancer tests positive for a protein called HER2. The main goal is to see if …

Matched conditions: HER2/NEU+ UTERINE SEROUS CARCINOMA

Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

HER2/NEU+ UTERINE SEROUS CARCINOMA

Get alerted when new HER2/NEU+ UTERINE SEROUS CARCINOMA trials appear

New drug trial targets Tough-to-Treat uterine cancer